Objective <p>To explore the action mechanisms of RGW that may treat anemia through the integration of network pharmacology, molecular docking, molecular dynamics simulation, and experiment verification.</p> Result <p>In particular, Ginsenoside Rg4, Ginsenoside Rg1, 3,3′,4,4′-Tetrahydroxy 2-methoxychalcone, Ginsenoside F1, Glycyrol, Chalconaringenin 4′-glucoside, Licochalcone B, 4′,7-Dihydroxyflavone, Glycycoumarin, and Ginsenoside Rh1 were the core components, while TP53, STAT3, PIK3R1, SRC, HIF-1α were the core targets. The GO and KEGG analyses indicated that RGW may modulate multiple biological processes and pathways, including the PI3K-Akt, HIF-1, and NF-kappa B signaling pathways, as well as EGFR tyrosine kinase inhibitor resistance. Molecular docking and molecular dynamics simulations showed good affinity between the active components and core targets of RGW, with stable binding within 100 nano seconds. Experiment verification revealed RGW could improve the routine blood markers of mice, and decrease the level of HIF-1α significantly.</p> Conclusion <p>RGW may treat anemia by regulating the PI3K-Akt and HIF-1 signaling pathways. It demonstrates the potential pharmacological mechanism of RGW in the treatment of anemia and provides a reference for clinical application of this formula.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Network pharmacology, molecular docking, molecular dynamics simulation, and experiment verification analysis to reveal the action mechanism of RenShen Guipi Wan in the treatment of anemia

  • Tingli Qu,
  • Nan Zhang,
  • Chen Li,
  • Xuyuan Liu,
  • Keming Yun,
  • Quan An

摘要

Objective

To explore the action mechanisms of RGW that may treat anemia through the integration of network pharmacology, molecular docking, molecular dynamics simulation, and experiment verification.

Result

In particular, Ginsenoside Rg4, Ginsenoside Rg1, 3,3′,4,4′-Tetrahydroxy 2-methoxychalcone, Ginsenoside F1, Glycyrol, Chalconaringenin 4′-glucoside, Licochalcone B, 4′,7-Dihydroxyflavone, Glycycoumarin, and Ginsenoside Rh1 were the core components, while TP53, STAT3, PIK3R1, SRC, HIF-1α were the core targets. The GO and KEGG analyses indicated that RGW may modulate multiple biological processes and pathways, including the PI3K-Akt, HIF-1, and NF-kappa B signaling pathways, as well as EGFR tyrosine kinase inhibitor resistance. Molecular docking and molecular dynamics simulations showed good affinity between the active components and core targets of RGW, with stable binding within 100 nano seconds. Experiment verification revealed RGW could improve the routine blood markers of mice, and decrease the level of HIF-1α significantly.

Conclusion

RGW may treat anemia by regulating the PI3K-Akt and HIF-1 signaling pathways. It demonstrates the potential pharmacological mechanism of RGW in the treatment of anemia and provides a reference for clinical application of this formula.